Report cover image

Global Therapeutic Radioligands Drug Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 204 Pages
SKU # APRC20280080

Description

Summary

According to APO Research, the global Therapeutic Radioligands Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Therapeutic Radioligands Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Therapeutic Radioligands Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Therapeutic Radioligands Drug market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Therapeutic Radioligands Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Therapeutic Radioligands Drug market include Novartis, Mundipharma, Bayer, Y-mAbs Therapeutics, Telix Pharmaceuticals, RadioMedix, Philogen, Orano Med and Nordic Nanovector, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Therapeutic Radioligands Drug, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Therapeutic Radioligands Drug, also provides the value of main regions and countries. Of the upcoming market potential for Therapeutic Radioligands Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Therapeutic Radioligands Drug revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Therapeutic Radioligands Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Therapeutic Radioligands Drug company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Therapeutic Radioligands Drug Segment by Company

Novartis
Mundipharma
Bayer
Y-mAbs Therapeutics
Telix Pharmaceuticals
RadioMedix
Philogen
Orano Med
Nordic Nanovector
Lantheus
Gilead Sciences
Fusion Pharmaceuticals
Curium Pharmaceuticals
Curasight
Clarity Pharmaceuticals
China Isotope & Radiation
Aurobindo Pharma
Actinium Pharmaceuticals
Therapeutic Radioligands Drug Segment by Type

Beta-emitting
Targeted Alpha Therapy
Therapeutic Radioligands Drug Segment by Application

Solid Tumor
Non Hodgkin Lymphoma
Therapeutic Radioligands Drug Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Therapeutic Radioligands Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Therapeutic Radioligands Drug key companies, revenue, market share, and recent developments.
3. To split the Therapeutic Radioligands Drug breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Therapeutic Radioligands Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Therapeutic Radioligands Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Therapeutic Radioligands Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Radioligands Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Radioligands Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Radioligands Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Radioligands Drug industry.
Chapter 3: Detailed analysis of Therapeutic Radioligands Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Therapeutic Radioligands Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Therapeutic Radioligands Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

204 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Therapeutic Radioligands Drug Market Size, 2020 VS 2024 VS 2031
1.3 Global Therapeutic Radioligands Drug Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Therapeutic Radioligands Drug Market Dynamics
2.1 Therapeutic Radioligands Drug Industry Trends
2.2 Therapeutic Radioligands Drug Industry Drivers
2.3 Therapeutic Radioligands Drug Industry Opportunities and Challenges
2.4 Therapeutic Radioligands Drug Industry Restraints
3 Therapeutic Radioligands Drug Market by Company
3.1 Global Therapeutic Radioligands Drug Company Revenue Ranking in 2024
3.2 Global Therapeutic Radioligands Drug Revenue by Company (2020-2025)
3.3 Global Therapeutic Radioligands Drug Company Ranking (2023-2025)
3.4 Global Therapeutic Radioligands Drug Company Manufacturing Base and Headquarters
3.5 Global Therapeutic Radioligands Drug Company Product Type and Application
3.6 Global Therapeutic Radioligands Drug Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Therapeutic Radioligands Drug Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Therapeutic Radioligands Drug Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Therapeutic Radioligands Drug Market by Type
4.1 Therapeutic Radioligands Drug Type Introduction
4.1.1 Beta-emitting
4.1.2 Targeted Alpha Therapy
4.2 Global Therapeutic Radioligands Drug Sales Value by Type
4.2.1 Global Therapeutic Radioligands Drug Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Therapeutic Radioligands Drug Sales Value by Type (2020-2031)
4.2.3 Global Therapeutic Radioligands Drug Sales Value Share by Type (2020-2031)
5 Therapeutic Radioligands Drug Market by Application
5.1 Therapeutic Radioligands Drug Application Introduction
5.1.1 Solid Tumor
5.1.2 Non Hodgkin Lymphoma
5.2 Global Therapeutic Radioligands Drug Sales Value by Application
5.2.1 Global Therapeutic Radioligands Drug Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Therapeutic Radioligands Drug Sales Value by Application (2020-2031)
5.2.3 Global Therapeutic Radioligands Drug Sales Value Share by Application (2020-2031)
6 Therapeutic Radioligands Drug Regional Value Analysis
6.1 Global Therapeutic Radioligands Drug Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Therapeutic Radioligands Drug Sales Value by Region (2020-2031)
6.2.1 Global Therapeutic Radioligands Drug Sales Value by Region: 2020-2025
6.2.2 Global Therapeutic Radioligands Drug Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Therapeutic Radioligands Drug Sales Value (2020-2031)
6.3.2 North America Therapeutic Radioligands Drug Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Therapeutic Radioligands Drug Sales Value (2020-2031)
6.4.2 Europe Therapeutic Radioligands Drug Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Therapeutic Radioligands Drug Sales Value (2020-2031)
6.5.2 Asia-Pacific Therapeutic Radioligands Drug Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Therapeutic Radioligands Drug Sales Value (2020-2031)
6.6.2 South America Therapeutic Radioligands Drug Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Therapeutic Radioligands Drug Sales Value (2020-2031)
6.7.2 Middle East & Africa Therapeutic Radioligands Drug Sales Value Share by Country, 2024 VS 2031
7 Therapeutic Radioligands Drug Country-level Value Analysis
7.1 Global Therapeutic Radioligands Drug Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Therapeutic Radioligands Drug Sales Value by Country (2020-2031)
7.2.1 Global Therapeutic Radioligands Drug Sales Value by Country (2020-2025)
7.2.2 Global Therapeutic Radioligands Drug Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.3.2 USA Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.4.2 Canada Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.6.2 Germany Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.7.2 France Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.7.3 France Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.9.2 Italy Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.10.2 Spain Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.11.2 Russia Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.14.2 China Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.14.3 China Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.15.2 Japan Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.17.2 India Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.17.3 India Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.18.2 Australia Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.22.2 Chile Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.24.2 Peru Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.26.2 Israel Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.27.2 UAE Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.29.2 Iran Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Therapeutic Radioligands Drug Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Therapeutic Radioligands Drug Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Therapeutic Radioligands Drug Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Novartis
8.1.1 Novartis Comapny Information
8.1.2 Novartis Business Overview
8.1.3 Novartis Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.1.4 Novartis Therapeutic Radioligands Drug Product Portfolio
8.1.5 Novartis Recent Developments
8.2 Mundipharma
8.2.1 Mundipharma Comapny Information
8.2.2 Mundipharma Business Overview
8.2.3 Mundipharma Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.2.4 Mundipharma Therapeutic Radioligands Drug Product Portfolio
8.2.5 Mundipharma Recent Developments
8.3 Bayer
8.3.1 Bayer Comapny Information
8.3.2 Bayer Business Overview
8.3.3 Bayer Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.3.4 Bayer Therapeutic Radioligands Drug Product Portfolio
8.3.5 Bayer Recent Developments
8.4 Y-mAbs Therapeutics
8.4.1 Y-mAbs Therapeutics Comapny Information
8.4.2 Y-mAbs Therapeutics Business Overview
8.4.3 Y-mAbs Therapeutics Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.4.4 Y-mAbs Therapeutics Therapeutic Radioligands Drug Product Portfolio
8.4.5 Y-mAbs Therapeutics Recent Developments
8.5 Telix Pharmaceuticals
8.5.1 Telix Pharmaceuticals Comapny Information
8.5.2 Telix Pharmaceuticals Business Overview
8.5.3 Telix Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.5.4 Telix Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
8.5.5 Telix Pharmaceuticals Recent Developments
8.6 RadioMedix
8.6.1 RadioMedix Comapny Information
8.6.2 RadioMedix Business Overview
8.6.3 RadioMedix Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.6.4 RadioMedix Therapeutic Radioligands Drug Product Portfolio
8.6.5 RadioMedix Recent Developments
8.7 Philogen
8.7.1 Philogen Comapny Information
8.7.2 Philogen Business Overview
8.7.3 Philogen Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.7.4 Philogen Therapeutic Radioligands Drug Product Portfolio
8.7.5 Philogen Recent Developments
8.8 Orano Med
8.8.1 Orano Med Comapny Information
8.8.2 Orano Med Business Overview
8.8.3 Orano Med Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.8.4 Orano Med Therapeutic Radioligands Drug Product Portfolio
8.8.5 Orano Med Recent Developments
8.9 Nordic Nanovector
8.9.1 Nordic Nanovector Comapny Information
8.9.2 Nordic Nanovector Business Overview
8.9.3 Nordic Nanovector Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.9.4 Nordic Nanovector Therapeutic Radioligands Drug Product Portfolio
8.9.5 Nordic Nanovector Recent Developments
8.10 Lantheus
8.10.1 Lantheus Comapny Information
8.10.2 Lantheus Business Overview
8.10.3 Lantheus Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.10.4 Lantheus Therapeutic Radioligands Drug Product Portfolio
8.10.5 Lantheus Recent Developments
8.11 Gilead Sciences
8.11.1 Gilead Sciences Comapny Information
8.11.2 Gilead Sciences Business Overview
8.11.3 Gilead Sciences Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.11.4 Gilead Sciences Therapeutic Radioligands Drug Product Portfolio
8.11.5 Gilead Sciences Recent Developments
8.12 Fusion Pharmaceuticals
8.12.1 Fusion Pharmaceuticals Comapny Information
8.12.2 Fusion Pharmaceuticals Business Overview
8.12.3 Fusion Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.12.4 Fusion Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
8.12.5 Fusion Pharmaceuticals Recent Developments
8.13 Curium Pharmaceuticals
8.13.1 Curium Pharmaceuticals Comapny Information
8.13.2 Curium Pharmaceuticals Business Overview
8.13.3 Curium Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.13.4 Curium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
8.13.5 Curium Pharmaceuticals Recent Developments
8.14 Curasight
8.14.1 Curasight Comapny Information
8.14.2 Curasight Business Overview
8.14.3 Curasight Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.14.4 Curasight Therapeutic Radioligands Drug Product Portfolio
8.14.5 Curasight Recent Developments
8.15 Clarity Pharmaceuticals
8.15.1 Clarity Pharmaceuticals Comapny Information
8.15.2 Clarity Pharmaceuticals Business Overview
8.15.3 Clarity Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.15.4 Clarity Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
8.15.5 Clarity Pharmaceuticals Recent Developments
8.16 China Isotope & Radiation
8.16.1 China Isotope & Radiation Comapny Information
8.16.2 China Isotope & Radiation Business Overview
8.16.3 China Isotope & Radiation Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.16.4 China Isotope & Radiation Therapeutic Radioligands Drug Product Portfolio
8.16.5 China Isotope & Radiation Recent Developments
8.17 Aurobindo Pharma
8.17.1 Aurobindo Pharma Comapny Information
8.17.2 Aurobindo Pharma Business Overview
8.17.3 Aurobindo Pharma Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.17.4 Aurobindo Pharma Therapeutic Radioligands Drug Product Portfolio
8.17.5 Aurobindo Pharma Recent Developments
8.18 Actinium Pharmaceuticals
8.18.1 Actinium Pharmaceuticals Comapny Information
8.18.2 Actinium Pharmaceuticals Business Overview
8.18.3 Actinium Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (2020-2025)
8.18.4 Actinium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
8.18.5 Actinium Pharmaceuticals Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.